HIV Testing Before Injectable PrEP: What Happens at the Appointment?
Why HIV testing remains essential before Apretude or Yeztugo, and what to ask at an injectable PrEP appointment.
Confirm eligibility, the exact medication, required testing, clinic and pharmacy, and every possible charge before relying on an offer.
Last researched: October 30, 2026 · Patient education; clinical schedules vary by drug
Twice-yearly or every-two-month PrEP injections can sound simpler than a daily pill. But fewer medication appointments do not mean you can skip HIV testing. HIV-negative status must be confirmed before starting PrEP, and the testing schedule depends on the product and your clinical history. Your prescriber also needs to know if you have recently taken PrEP or PEP or have possible symptoms of an acute HIV infection.
Why testing is especially important for long-acting drugs
PrEP medicines are designed for people who do not have HIV. If someone starts or continues PrEP with unrecognized HIV infection, the drug regimen is not a complete HIV treatment and may contribute to drug resistance. That is why the FDA's Yeztugo label includes specific warnings about HIV testing, and CDC's clinical guidance emphasizes appropriate antigen/antibody and RNA testing in relevant situations.
A negative home oral-fluid rapid test alone may be insufficient. CDC advises against relying on oral rapid tests to screen people for starting or continuing PrEP because they are less sensitive than appropriate blood tests for detecting recent HIV infection. Ask your clinical team what sample and test are required for the medication you are considering.
What the first visit generally involves
The clinician reviews HIV prevention goals, recent exposures, past PrEP or PEP, medications, symptoms and test history. An appropriate HIV test is performed; other screening may be needed depending on the specific product and your health profile. A provider may also discuss other STI screening, side effects, whether a medication is right for you and the timing of subsequent visits.
Do not assume all testing happens during the same appointment or that a negative result obtained months earlier will be accepted for an injection today. Ask which results must be available before dosing and where follow-up will take place. Clinical staff should explain how you receive results privately and whom to contact about an unexpected result.
Yeztugo and Apretude are not on the same visit calendar
Apretude uses an initial injection, another approximately one month later and then a routine every-two-month schedule; monitoring is tied to those visits under the clinician's guidance. Yeztugo is a different drug with injections approximately every six months and a product-specific initiation and HIV-testing process. Neither should be treated as a drop-in substitute for the other.
Some patients switching from pills or a different injectable require additional HIV testing or a tailored transition plan. That is a medical decision. A web guide can help you organize questions, not tell you whether to skip a test or take a bridging dose.
A practical appointment checklist
- Bring an accurate medication list and the dates of your recent PrEP or PEP doses, if any.
- Tell the clinician about possible HIV exposures or symptoms, even if you are unsure they matter.
- Ask what HIV tests are being ordered and when results will be available.
- Confirm whether other required tests, STI screening or clinical assessments are due.
- Ask the office to verify insurance for both medication and administration.
- Record the next visit date and a reliable contact method for rescheduling.
If a test is unclear or suggests HIV, the clinician will need a specific diagnostic and treatment pathway rather than simply administering PrEP. Resist the urge to interpret an ambiguous lab result without professional input.
What if you're late for an injection?
Contact the administering clinic promptly. Long-acting drugs remain in the body, but that does not guarantee continued protection if an injection is missed. The FDA label discusses product-specific missed-dose and discontinuation precautions. The safe plan depends on exactly which drug was used, when your last dose occurred, HIV test results and other circumstances. Do not follow a generic online replacement timetable.
If you may have had an HIV exposure within the last 72 hours and are concerned about protection, get urgent professional evaluation for PEP. Do not wait for a scheduled PrEP appointment to ask.
What you might actually pay for tests
Even where a medication has no patient copay, the laboratory and administration site may bill separately. Many plans cover recommended PrEP preventive services without cost-sharing, but a wrong billing code, network issue or plan-specific requirement can create a bill. Ask the provider to check coverage and explain any estimated out-of-pocket charge before the appointment.
You can compare injectable PrEP options, insurance barriers and Yeztugo access.
Different tests answer different questions
Routine HIV screening and testing for a very recent infection are not identical. Clinicians consider the type of test, its detection window, recent symptoms and any previous PEP or PrEP use. An oral-fluid rapid test alone is not the preferred basis for starting injectable PrEP. With long-acting medicines, identifying HIV infection promptly is important because using a prevention-only drug during undiagnosed infection can contribute to resistance.
| Test or question | What the clinician considers | Why it matters |
|---|---|---|
| Laboratory blood antigen/antibody test | Current HIV status and recent exposure history | A core component of PrEP evaluation |
| HIV RNA/NAT test | Whether additional testing is appropriate for very recent infection or prior medication use | Can help clarify acute infection in selected contexts |
| Symptoms and recent exposure | Fever, rash, recent illness, timing of possible exposure | May change how results are interpreted |
| Previous PEP/PrEP | Oral medicine and recent long-acting injections | Can affect appropriate testing strategy |
| Other monitoring | Medication-specific clinical assessments | Determines if the selected prevention method fits |
Yeztugo and Apretude: why a single universal checklist fails
The FDA labeling for Yeztugo requires HIV testing before initiation and each subsequent injection using an appropriate test for acute or primary infection. CDC's lenacapavir recommendation discusses laboratory blood-based antigen/antibody screening near injection, with additional HIV RNA testing when available at initiation. Apretude has its own testing instructions and follow-up schedule. A clinic should use the current label and professional guidance for the exact product rather than reusing a generic checklist.
You do not need to decide which blood test to order yourself. It is useful, however, to ask whether testing will happen at the clinic, at a partner lab or before the visit, and who will review results. If a result is unclear, the clinician may defer treatment while status is confirmed; that is a safety measure, not a personal failure.
A missed-visit plan is part of the prescription
Long-acting injections depend on follow-up timing. Before the first appointment, ask how the clinic schedules the next dose, how you will be reminded, and which phone number to call if travel, insurance or illness interferes. Each medication has label-specific instructions for delayed or missed injections. Do not use an oral or injectable workaround suggested by a generic search result; ask your prescribing team about the approved plan for your medication.
What to tell your clinician before testing
Report recent PEP or PrEP use, possible HIV exposures, viral-like symptoms and all medications or supplements that might interact. If you are receiving HIV testing elsewhere, provide the actual test type and date. Your clinician may repeat testing rather than relying on a screenshot of a home result. Confidentiality concerns and insurance issues are good reasons to ask for coordination, not reasons to skip medically necessary testing.
A good closing question at the clinic
“Before I leave, can you tell me which test we used, whether further testing is needed, who will contact me with results, and the date of my next visit?” That short summary makes ongoing care less confusing and helps catch an appointment that was never booked.
Frequently asked questions
Can I use an at-home HIV test before every shot?
Do not assume so. The accepted testing method depends on the drug and clinical situation. Appropriate blood testing is important, and the clinician should explain the requirements.
Do long-acting shots eliminate STI screening?
No. HIV PrEP does not prevent gonorrhea, chlamydia or syphilis, and clinicians may recommend STI screening as part of preventive care.
Is a recent negative test enough to start injections?
The clinician determines which tests and timing satisfy the drug label and current guidance. A result from another provider may or may not be sufficient.